Pharmacological and clinical evaluation of a new anti-HIV drug, rilpivirineHE Ri-cai, GUO Chang-bin, ZHOU Hua, LI Zhen-zhong947-951
A look into the EU post-marketing sampling and testing model and its inspiration to ChinaSUN Ling-ling, BI Kai-shun956-959
FDA Guidance for Industry Postmarketing Studies and Clinical Trials in USDONG Duo, SUN Li-hua, WANG Dan960-963
Research on the R&D incentives of FDA in the new drug registration and approvalYANG Li, LIAN Gui-yu, XING Hua, HUANG Zhe964-968
Study on pharmacokinetic profile of PVP-coated norcantharidin-chitosan nanoparticles in rats by HPLC-MS/MSDING Xin-yuan, WANG Wen-juan, GU Zong-lin, HONG Cheng-jiao, ZHANG Xue-nong969-974
Effects of metabolizing enzyme polymorphisms on drug related neurotoxicityZHOU Hui, TANG Na-ping, MA Jing975-979
Inhibitory effects of celastrol on primary hepatocytes of HBV transgenic miceZHANG Xin-rui, YI Xue-rui, YUAN You-cheng, LI Na, KONG Xiang-ping980-982,988
GL331, a topoisomerase Ⅱ inhibitor, induces growth arrest in HepG2 cells in vitroWANG Ya-jie, CHEN Xiao-guang, XIAO Zhi-yan, LIU Geng-tao, SUN Hua983-988
Nonhuman primates as animal models for developmental and reproductive toxicity studyYUAN Fang, PAN Xiao-liang, LIN Hai-xia, WANG Qing-li, CHANG Yan989-993,1006